Breaking Finance News

Dexcom (NDAQ:DXCM) target price raised to $76.00, reported today by Barclays Capital

Dexcom (NDAQ:DXCM) had its price target upped to $76.00 by Barclays Capital in an issued report issued 9/15/2017. The new target price indicates a possible upside of 0.08% from the company's most recent stock price close.

Boasting a price of $70.42, Dexcom (NDAQ:DXCM) traded -1.60% lower on the day. The last stock close price is down -4.02% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. The company has recorded a 50-day moving average of $72.36 and a 200-day moving average of $74.17. 356,858 shares of the stock were exchanged, down from an avg. volume of 1,182,340

Recent Performance Chart

Dexcom (NDAQ:DXCM)

Dexcom has with a one year low of $57.68 and a one year high of $94.79 and has a market capitalization of $0.

General Company Details For Dexcom (NDAQ:DXCM)

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *